Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
| العنوان: | Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages |
|---|---|
| المؤلفون: | Olusola A Ogunsanya, Francis Baimba, Johan Holst, Simji S. Gomerep, Robert F. Garry, Erica Ollmann Saphire, Peter O. Okokhere, Raju Lathigra, Viktoriya Borisevich, Diana K. S. Nelson, Luis M. Branco, Benevolence Ebo, Sylvanus Okogbenin, John S. Schieffelin, John Aiyepada, Mambu Momoh, Robert W. Cross, Megan L. Heinrich, Anatoliy P. Koval, Matthew L. Boisen, Thomas W. Geisbert, Augustine Goba, Megan M. Rowland, Andrew R. Hoffmann, Onikepe A. Folarin, E. E. Ella, John Demby Sandi, Christian T. Happi, Chinedu A Ugwu, lkponmwosa Odia, Johnson Etafo, Brandon J. Beddingfield, Macdonald Nonso Onyechi, Donald S. Grant, Jeffrey G. Shaffer, Rashidat Adeyemi, M. Aminu, Sophia A. Koval, Kathryn M. Hastie, Duane J. Bush, George O. Akpede, Philomena Eromon, Matthew Afam Eke, Danny Asogun, Irina Aimukanova, Testimony J. Olumade |
| المصدر: | Scientific Reports, Vol 10, Iss 1, Pp 1-19 (2020) Scientific Reports |
| بيانات النشر: | Nature Publishing Group, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Immunology, Nigeria, lcsh:Medicine, Cross Reactions, medicine.disease_cause, Antibodies, Viral, Microbiology, Neutralization, Article, Antibodies, Sierra leone, Sierra Leone, 03 medical and health sciences, 0302 clinical medicine, Immune system, Lassa Fever, medicine, Humans, 030212 general & internal medicine, Survivors, Lassa fever, Lassa virus, lcsh:Science, Antigens, Viral, Multidisciplinary, biology, lcsh:R, Genetic Variation, medicine.disease, Virology, Recombinant Proteins, Nucleoprotein, Immunity, Humoral, 030104 developmental biology, Nucleoproteins, Humoral immunity, biology.protein, Immunization, lcsh:Q, Antibody |
| الوصف: | Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI’s (Coalition for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential of the human immune system to mount cross-reactive and cross-protective humoral immune responses to antigens from the most prevalent LASV lineages, which are lineages II and III in Nigeria and lineage IV in Sierra Leone. IgG and IgM present in the blood of Lassa fever survivors from Nigeria or Sierra Leone exhibited substantial cross-reactivity for binding to LASV nucleoprotein and two engineered (linked and prefusion) versions of the glycoproteins (GP) of lineages II–IV. There was less cross-reactivity for the Zinc protein. Serum or plasma from Nigerian Lassa fever survivors neutralized LASV pseudoviruses expressing lineage II GP better than they neutralized lineage III or IV GP expressing pseudoviruses. Sierra Leonean survivors did not exhibit a lineage bias. Neutralization titres determined using LASV pseudovirus assays showed significant correlation with titres determined by plaque reduction with infectious LASV. These studies provide guidance for comparison of humoral immunity to LASV of distinct lineages following natural infection or immunization. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c3b67d4e980aad8fab219983ac6ac2a http://link.springer.com/article/10.1038/s41598-020-72539-w |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....5c3b67d4e980aad8fab219983ac6ac2a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|